RBC Capital analyst Shagun Singh lowered the firm’s price target on Globus Medical (GMED) to $95 from $101 and keeps an Outperform rating on the shares. The company issued Q1 results that missed expectations due to softer Enabling Technology deal closures, temporary integration-related supply chain disruption, and timing of distributor orders, the analyst tells investors in a research note. RBC adds however that the post-earnings decline is an over-reaction, recommending buying on weakness.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Morning Movers: Pinterest, Lyft jump following quarterly results
- Globus Medical price target lowered to $105 from $115 at Roth Capital
- Globus Medical price target lowered to $80 from $100 at Piper Sandler
- Globus Medical price target lowered to $77 from $88 at BTIG
- Globus Medical Faces Challenges: Hold Rating Amid Revenue Miss and Cautious Outlook